Effects of anti-estrogens on cell invasion and survival in pituitary adenoma cells: A systematic study. Issue 187 (March 2019)

• Record Type: Journal Article
• Authors: Hannen, Ricarda; Steffani, Marcella; Voellger, Benjamin; Carl, Barbara; Wang, Junwen; Bartsch, Jörg W.; Nimsky, Christopher
• Is Part Of: Journal of steroid biochemistry and molecular biology. Issue 187(2019)
• Page Start: 88
• Page End: 96
• Publication Date: 2019-03
• Subjects: DAPI 4′, 6-diamidino-2-phenylindole -- ER estrogen receptor -- FCS fetal calf serum -- PFA paraformaldehyde -- SERM selective estrogen receptor modulators -- SERD selective estrogen receptor degrader -- 5-FU 5-Fluorouracil; Pituitary adenomas -- Estrogen -- Anti-estrogens -- SERM -- SERD -- Cell migration -- Invasion -- Apoptosis; Steroid hormones -- Periodicals; Biochemistry -- Periodicals; Hormones -- Periodicals; Molecular Biology -- Periodicals; Hormones stéroïdes -- Périodiques; Steroid hormones; Periodicals; 572.579
• DOI: 10.1016/j.jsbmb.2018.11.005
• Languages: English
• ISSNs: 0960-0760

Abstract

Abstract: Although the molecular mechanisms underlying the formation of pituitary adenomas are largely unknown, it is clear that estrogen plays a key role in the pathogenesis of pituitary adenomas. Though this is exemplified by an investigation of fulvestrant in the pituitary adenoma cell line GH3, no systematic studies on the effects of selective estrogen receptor modulators (SERMs) on functional properties of pituitary adenoma cell lines to modulate cell migration, cell invasion, and cell survival are available. Here we analyzed the effects of fulvestrant and three SERMs, bazedoxifene, clomifene, and raloxifene, on pituitary adenomas cell lines AtT20, TtT/GF, and GH3. In cell survival assays, clomifene was shown to be the most potent compound in all three cell lines with IC50 values ranging between 2, 6, and 10 μM, respectively, depending on the cell type. Raloxifene and bazedoxifene were also effective but to a lower extent. Also, all SERMs affected migratory and invasive behavior of pituitary adenoma cells. Mechanistically, treatment of cells with SERMs caused cell apoptosis, as demonstrated by Caspase 3/7 activity and western blot assays. In addition, western blots demonstrate activation of p53 in TtT/GF cells and loss of ERK1/2 activation in AtT20 cells. In contrast, fulvestrant was only effective in GH3 cells. Thus, the general applicability of SERMs for pituitary adenoma cells might be promising in clinical applications for the treatment of pituitary adenomas.